Renal Failure-Related Mortality in Multiple Myeloma: United States Trends From 1999 to 2020.

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-06-06 DOI:10.1016/j.clml.2025.06.002

Manayiel Rehmat, Ahmed Raza, Fnu Kalpina, Mateen Ahmad, Eman Alamgir, Moeen Ikram, Eiman Zeeshan

{"title":"Renal Failure-Related Mortality in Multiple Myeloma: United States Trends From 1999 to 2020.","authors":"Manayiel Rehmat, Ahmed Raza, Fnu Kalpina, Mateen Ahmad, Eman Alamgir, Moeen Ikram, Eiman Zeeshan","doi":"10.1016/j.clml.2025.06.002","DOIUrl":null,"url":null,"abstract":"Background: Multiple myeloma (MM) causes the deposition of monoclonal light chains in kidney tubules and glomeruli. This nephrotoxicity is exacerbated by nephrotoxic medicines, sepsis, dehydration and hypercalcemia. This study assesses the temporal, racial, sex-based, and regional disparities in mortality due to renal failure associated with MM in the US from 1999 to 2020.Methods: Data was extracted from the CDC WONDER database. Age-adjusted mortality rates (AAMRs) per 100,000 persons were determined. The change in AAMRs was examined through annual percent Change (APC) and the average annual percent change (AAPC) using Joinpoint regression. Patients aged 45-85+ years were identified using ICD-10 codes for Multiple Myeloma (C90.0) as the UCD and renal failure (N17-N19) as MCD.Results: Between 1999 and 2020, 42,093 total deaths were found. Overall AAMR declined from 1.94 in 1999 to 1.18 in 2020 (AAPC: -2.10). Men had higher overall AAMR (2.16) than women (1.26). NH Blacks had the highest overall AAMR (3.61), followed by NH Whites (1.47), Hispanics (1.38), and NH Asians (0.82). AAMR also varied substantially by region (Midwest: 1.66; South: 1.65; West: 1.58; Northeast: 1.54). Nonmetropolitan areas had higher AAMR (1.69) than metropolitan areas (1.61). States in the top percentiles were District of Columbia, Maryland and South Carolina.Conclusions: The overall AAMR for renal failure-associated MM mortality decreased from 1999 to 2020. We observed the highest AAMR in males, NH Blacks, Midwest, and nonmetropolitan areas of the US. However, NH Blacks also exhibited the greatest decrease in mortality over the study period.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.06.002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Multiple myeloma (MM) causes the deposition of monoclonal light chains in kidney tubules and glomeruli. This nephrotoxicity is exacerbated by nephrotoxic medicines, sepsis, dehydration and hypercalcemia. This study assesses the temporal, racial, sex-based, and regional disparities in mortality due to renal failure associated with MM in the US from 1999 to 2020.

Methods: Data was extracted from the CDC WONDER database. Age-adjusted mortality rates (AAMRs) per 100,000 persons were determined. The change in AAMRs was examined through annual percent Change (APC) and the average annual percent change (AAPC) using Joinpoint regression. Patients aged 45-85+ years were identified using ICD-10 codes for Multiple Myeloma (C90.0) as the UCD and renal failure (N17-N19) as MCD.

Results: Between 1999 and 2020, 42,093 total deaths were found. Overall AAMR declined from 1.94 in 1999 to 1.18 in 2020 (AAPC: -2.10). Men had higher overall AAMR (2.16) than women (1.26). NH Blacks had the highest overall AAMR (3.61), followed by NH Whites (1.47), Hispanics (1.38), and NH Asians (0.82). AAMR also varied substantially by region (Midwest: 1.66; South: 1.65; West: 1.58; Northeast: 1.54). Nonmetropolitan areas had higher AAMR (1.69) than metropolitan areas (1.61). States in the top percentiles were District of Columbia, Maryland and South Carolina.

Conclusions: The overall AAMR for renal failure-associated MM mortality decreased from 1999 to 2020. We observed the highest AAMR in males, NH Blacks, Midwest, and nonmetropolitan areas of the US. However, NH Blacks also exhibited the greatest decrease in mortality over the study period.

查看原文本刊更多论文

多发性骨髓瘤肾衰竭相关死亡率：1999年至2020年美国趋势

背景：多发性骨髓瘤（MM）引起肾小管和肾小球内单克隆轻链的沉积。肾毒性可因肾毒性药物、败血症、脱水和高钙血症而加重。本研究评估了1999年至2020年美国MM相关肾衰竭死亡率的时间、种族、性别和地区差异。方法：数据从CDC WONDER数据库中提取。确定了每10万人的年龄调整死亡率（AAMRs）。采用关节点回归，通过年变化百分比（APC）和平均年变化百分比（AAPC）检测AAMRs的变化。年龄45-85岁以上的患者采用ICD-10编码诊断多发性骨髓瘤（C90.0）为UCD，肾衰竭（N17-N19）为MCD。结果：1999年至2020年间，共发现42,093例死亡。总体AAMR从1999年的1.94下降到2020年的1.18 （AAPC: -2.10）。男性的总体AAMR（2.16）高于女性（1.26）。NH黑人的总体AAMR最高（3.61），其次是NH白人（1.47），西班牙裔（1.38）和NH亚洲人（0.82）。AAMR也因地区而异(中西部：1.66；南:1.65;西方:1.58;东北:1.54)。非首都地区的AAMR（1.69）高于首都地区（1.61）。排名靠前的几个州是哥伦比亚特区、马里兰州和南卡罗来纳州。结论：肾衰竭相关MM死亡率的总体AAMR从1999年到2020年下降。我们观察到最高的AAMR在男性，NH黑人，中西部和非大都市地区的美国。然而，NH黑人在研究期间也表现出最大的死亡率下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.